Clinical trial · no report yet · Phase 3
TRAIN-2
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
- NCT01996267 ↗
- Active not recruiting
- The Netherlands Cancer Institute
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 12 | |
| Podcasts | 6 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer; HER2 Positive
- Interventions
- PTC+Pertuzumab; FEC-T+Pertuzumab
- Arms
- FEC-T +Pertuzumab · Active comparator
- PTC+Pertuzumab · Active comparator
- Enrollment
- 437
- Primary outcomes
- Number of patients with pathological complete response
- Sponsor
- The Netherlands Cancer Institute with Roche Pharma AG, Borstkanker Onderzoek Groep
- Start
- Dec 2013
- Primary completion
- Dec 2018
- Results posted
- No
- Registry record
- NCT01996267 · updated Mar 29, 2024
Publications
linked from the registry- van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. PubMed 34014249
- van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6. PubMed 30413379